Market stabilization confirmed; Strong profitability and cash flow
. - Reported revenue down 6.1% to EUR 581.4 million (CER minus 7.7%); revenues in line with markets - EMEA (excl. Spai…
. - Reported revenue down 6.1% to EUR 581.4 million (CER minus 7.7%); revenues in line with markets - EMEA (excl. Spai…
. - Umsatz mit CHF 877,7 Mio. (EUR 581,4 Mio.) im Rahmen des Marktes; 6,1 Prozent unter Vorjahr (kWk -7,7 Prozent) - W…
. - Reported revenue down 6.1% to EUR 581.4 million (CER minus 7.7%); revenues in line with markets - EMEA (excl. Spai…
. - Growth in line with market despite deferred scanner revenues and unfavorable country mix - Reported revenue growth…
. - Revenue growth in Q1 at constant exchange rates (CER) minus 9% at EUR 147.0 million - Reported revenue growth minu…
At the 33rd IDS (International Dental Show), Nobel Biocare will globally launch its innovative state-of-the-art NobelPro…
. - Globale Markteinführung des neuen NobelProcera(TM) Systems, neuer Materialien und einer erweiterten prothetischen P…
. - Revenue growth at constant exchange rates (CER) minus 4% at EUR 619.2 million - Change in commercial approach in Q…
. - Umsatz in Lokalwährungen mit CHF 982.1 Mio. (EUR 619.2 Mio.) 4 Prozent unter Vorjahr - Änderung der Verkaufsbedin…
Nobel Biocare announced today that it has signed an agreement to buy 100% of BioCad Medical Inc., a leading developer of…